Medicare approved the groundbreaking new cell-based gene therapy drug, Encelto, for use in the ambulatory surgical center setting, effective for claims with dates of service on or after October 1, 2025. This article details how to bill for…
Effective January 1, 2026, the application of the JW and JZ modifiers has changed for certain skin substitutes per the calendar year (CY) 2026 final rule. This article describes the changes.
Medicare Part B covers various colorectal cancer (CRC) screening tests furnished to individuals for the purpose of early detection of colon cancer. Learn more about these lifesaving preventive services.